Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 60 DEGREES PHARMACEUTICALS, INC.SXTP · Entity 8389 | Chief Operating Officer | September 26, 2024 | August 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
60 DEGREES PHARMACEUTICALS, INC.
Report date September 26, 2024 · Filed August 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.85 · Expires 2034-09-26 | Direct | 4,167 |
Reported balance
After 2024-09-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-26 · Grant · Acquired 4,167 · Balance 4,167 F1: The options were granted pursuant to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The options shall vest and become exercisable in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024. The options have a maximum term of 10 years from the date of grant. F2: This Form 4 is being filed late due to an inadvertent administrative error. F3: All information has been retroactively adjusted to reflect the 1-for-5 reverse stock split effected by the Issuer on February 24, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted pursuant to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The options shall vest and become exercisable in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024. The options have a maximum term of 10 years from the date of grant.
F2: This Form 4 is being filed late due to an inadvertent administrative error.
F3: All information has been retroactively adjusted to reflect the 1-for-5 reverse stock split effected by the Issuer on February 24, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2025 Filed Aug 15, 2025 01:23 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | GrantCommon Stock | 4,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-076983 · ownership.xml · nonDerivative · entry 1 Landon Kristen · CIK 0002053910 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,540 F1 · security: This Form 4 is being filed late due to an inadvertent administrative error. F2 · security: The number of shares has been adjusted to reflect the 1-for-5 reverse stock split effected by the Issuer on February 24, 2025. Read SEC document |
| September 26, 2024 Filed Aug 15, 2025 01:24 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | GrantStock Options (Right to Buy) · Derivative | 4,167 | $0.00 Strike: $6.85 | $0.00 |
DisclosureSEC source: 0001213900-25-076984 · ownership.xml · derivative · entry 1 Landon Kristen · CIK 0002053910 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,167 Underlying: Common Stock · 4,167 shares Expires 2034-09-26 F1 · security: The options were granted pursuant to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The options shall vest and become exercisable in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024. The options have a maximum term of 10 years from the date of grant. F2 · security: This Form 4 is being filed late due to an inadvertent administrative error. F3 · security: All information has been retroactively adjusted to reflect the 1-for-5 reverse stock split effected by the Issuer on February 24, 2025. F1 · derivative.exercise_date: The options were granted pursuant to the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The options shall vest and become exercisable in five equal tranches on the last date of each fiscal year, with the first vesting date being December 31, 2024. The options have a maximum term of 10 years from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.